

Appl. No. 10/044,645
Amendment Dated March 10, 2004
Reply to Office Action of September 11, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (previously presented): A composition comprising *Serenoa repens* or an extract thereof and a sympathomimetic agent, wherein the sympathomimetic agent is synephrine, wherein the composition is suitable for oral administration.

Claim 2 (previously presented): The composition of claim 1, wherein the *Serenoa repens* or extract thereof has anti-adrenergic activity.

Claim 3 (original): The composition of claim 2, wherein the anti-adrenergic activity is inhibition of agonist binding to the alpha-adrenergic receptor.

Claim 4 (previously presented): The composition of claim 1, wherein the composition is in a pharmaceutically acceptable form.

Claims 5-8 (canceled)

Claim 9 (previously presented): A composition comprising *Serenoa repens* or an extract thereof and a sympathomimetic agent, wherein the sympathomimetic agent is an extract of *Citrus aurantium* containing synephrine therein or other natural source of synephrine, wherein the composition is suitable for oral administration.

Claim 10 (previously presented): A method of alleviating the side effects of a sympathomimetic agent, the method comprising administering *Serenoa repens* or extract thereof, and a sympathomimetic agent, to a human or animal in need thereof;

wherein the *Serenoa repens* or extract thereof is administered in an amount effective to reduce side effects of the sympathomimetic agent.

3434551-1

Appl. No. 10/044,645
Amendment Dated March 10, 2004
Reply to Office Action of September 11, 2003

Claim 11 (original): The method of claim 10, wherein the *Serenoa repens* or extract thereof has anti-adrenergic activity.

Claim 12 (original): The method of claim 11, wherein the anti-adrenergic activity is inhibition of agonist binding the alpha-adrenergic receptor.

Claim 13 (original): The method of claim 10, wherein the *Serenoa repens* or extract thereof is administered in a pharmaceutically acceptable form.

Claim 14 (canceled)

Claim 15 (original): The method of claim 10, where the sympathomimetic agent comprises ephedrine or an ephedrine related alkaloid.

Claim 16 (original): The method of claim 10, where the sympathomimetic agent comprises a mixture of ephedrine or ephedrine related alkaloid and caffeine.

Claim 17 (original): The method of claim 10, where the sympathomimetic agent is selected from the group consisting of synephrine, pseudoephedrine and phenylpropanolamine.

Claim 18 (previously presented): The method of claim 10, wherein the sympathomimetic agent is ma huang or other natural sources of ephedrine or related alkaloids, or an extract of *Citrus aurantium* containing synephrine therein or other natural source of synephrine.

Claim 19 (original): The method of claim 10, wherein the *Serenoa repens* or extract thereof is administered at least 24 hours prior to administration of the sympathomimetic agent.

Claim 20 (original): The composition of claim 9, wherein the *Serenoa repens* or extract thereof has anti-adrenergic activity.

Claim 21 (original): The composition of claim 20, wherein the anti-adrenergic activity is inhibition of agonist binding the alpha-adrenergic receptor.

Appl. No. 10/044,645
Amendment Dated March 10, 2004
Reply to Office Action of September 11, 2003

Claim 22 (original): The composition of claim 9, wherein the *Serenoa repens* or extract thereof is administered in a pharmaceutically acceptable form.

Claim 23 (previously presented): The method of claim 10 wherein the *Serenoa repens* or extract thereof and the sympathomimetic agent are administered by a route selected from the group consisting of topical, sublingual, transdermal, oral, parenteral and implantation.

Claim 24 (previously presented): The method of claim 19 wherein the *Serenoa repens* or extract thereof and the sympathomimetic agent are administered by a route selected from the group consisting of topical, sublingual, transdermal, oral, parenteral and implantation.

Claim 25 (currently amended): A composition comprising *Serenoa repens* or an extract thereof and a sympathomimetic agent, wherein the sympathomimetic agent is an extract of *Citrus aurantium* containing synephrine therein, or other natural source of synephrine wherein the sympathomimetic agent is at a concentration between 5-5,000, and wherein the composition is suitable for oral administration.

Claim 26 (previously presented): The composition of claim 25, wherein the *Serenoa repens* or extract thereof has anti-adrenergic activity.

Claim 27 (previously presented): The composition of claim 26, wherein the anti-adrenergic activity is inhibition of agonist binding to the alpha-adrenergic receptor.

Claim 28 (previously presented): The composition of claim 25, wherein the composition is in a pharmaceutically acceptable form.

Claim 29 (cancelled).

Claim 30 (cancelled).